Stockscreener 앱 받기
8.36
0.97%
0.08
시간 외 거래:
8.20
-0.16
-1.91%
전일 마감가:
$8.28
열려 있는:
$8.18
하루 거래량:
734.95K
Relative Volume:
0.79
시가총액:
$431.48M
수익:
$170.44M
순이익/손실:
$-193.88M
주가수익비율:
-2.2269
EPS:
-3.7541
순현금흐름:
$-126.38M
1주 성능:
-7.93%
1개월 성능:
-0.59%
6개월 성능:
-5.96%
1년 성능:
-1.65%
1일 변동 폭
$8.02
$8.46
1주일 범위
$8.02
$9.10
52주 변동 폭
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.36 | 427.36M | 170.44M | -193.88M | -126.38M | -3.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class - PharmiWeb.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - marketscreener.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action - The Joplin Globe
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP - Stock Titan
Regenxbio reports Duchenne gene therapy progress as stock slides on mixed signals - MSN
Ideas Watch: What is the earnings history of REGENXBIO Inc2026 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
Regenxbio says its gene therapy for muscle disorder showed no evidence of liver injury in study - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 – Company AnnouncementFT.com - Financial Times
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST) Announced by Holzer & Holzer, LLC - marketscreener.com
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire
Invenomic Capital Management LP Makes New $4.12 Million Investment in REGENXBIO Inc. $RGNX - MarketBeat
RGNX's "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com Nigeria
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Regenxbio reports positive interim data for Duchenne gene therapy By Investing.com - Investing.com Nigeria
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (2026-03-15) - Seeking Alpha
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - bhpioneer.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
Integral Health Asset Management LLC Acquires 400,000 Shares of REGENXBIO Inc. $RGNX - MarketBeat
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
RGNX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Positive interim data for Regenxbio’s gene therapy in DMD - The Pharmaletter
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com Nigeria
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
17:55 ETRGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - Longbridge
REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 5,124 Shares - MarketBeat
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com Nigeria
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock By Investing.com - Investing.com India
REGENXBIO (RGNX) CMO sells 5,124 shares under 10b5-1 plan - Stock Titan
MDA: Vinay away, AA in play for Regenxbio gene therapy? - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST - Stock Titan
Stifel reiterates Regenxbio stock rating on Duchenne trial data - Investing.com UK
Stifel reiterates Regenxbio stock rating on Duchenne trial data By Investing.com - Investing.com Canada
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, - GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):